Welcome to our dedicated page for C4 Therapeutics SEC filings (Ticker: CCCC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
C4 Therapeutics, Inc. filings document the regulatory record for a clinical-stage biopharmaceutical company focused on targeted protein degradation and oncology drug development. Its 8-K reports cover material agreements, including the Roche research collaboration and license agreement for degrader-antibody conjugates, clinical and regulatory disclosures, operating results, business updates, and capital-structure matters involving common stock sales arrangements.
Proxy and governance filings describe board matters, executive compensation, equity awards, shareholder voting items, and by-law provisions, including forum-selection amendments. The filing record also includes Regulation FD disclosures, clinical presentation exhibits for cemsidomide, and other material-event reports tied to the company’s pipeline, collaborations, and public-company governance.
C4 Therapeutics reported a first‑quarter 2026 net loss of $25.1 million, slightly improved from $26.3 million a year earlier, as collaboration revenue was $6.2 million and operating expenses eased modestly. Cash, cash equivalents and marketable securities totaled $268.3 million as of March 31, 2026, which management believes will fund operations for at least 12 months.
The company continues to focus on targeted protein degradation, advancing lead drug cemsidomide in multiple myeloma through a Phase 2 trial and a Phase 1b combination study with elranatamab. Lung cancer candidate CFT8919 is in Phase 1 in Greater China via Betta Pharma. Collaborations with Roche, Biogen, Betta Pharma and MKDG provided milestone and research revenue, including a $2.0 million Biogen milestone in the quarter, and a new April 2026 Roche DAC agreement added a $20.0 million upfront payment and more than $1.0 billion in potential milestones.
C4 Therapeutics reported first quarter 2026 results and highlighted progress in its protein degrader pipeline. Revenue was $6.2 million, down from $7.2 million a year earlier, mainly reflecting the conclusion and reprioritization of Merck collaborations. R&D expense declined to $24.6 million from $27.1 million, while G&A expense remained steady at $9.3 million.
Net loss narrowed slightly to $25.1 million, or $0.20 per share, compared with $26.3 million, or $0.37 per share, in the prior-year quarter. Cash, cash equivalents and marketable securities were $268.3 million as of March 31, 2026, and the company expects this to fund operations to the end of 2028.
The company advanced cemsidomide in multiple myeloma with Phase 2 and Phase 1b trials enrolling and plans an additional Phase 1b combination trial in 2027. It also expanded its long-term partnership with Roche through a new degrader‑antibody conjugate collaboration, including a $20 million upfront payment, and decided not to advance CFT8919 in non-small cell lung cancer outside Greater China.
C4 Therapeutics (CCCC) filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, describing a clinical-stage biopharmaceutical company advancing targeted protein degraders via its proprietary TORPEDO platform. The report highlights two clinical programs—cemsidomide (IKZF1/3) in multiple myeloma and CFT8919 (EGFR L858R) in NSCLC—and partnerships with Merck KGaA, Roche, Betta Pharma, Pfizer, and Biogen. Management reports net losses of $105.0M in 2025 and $105.3M in 2024, a market value of $100.05M for non-affiliate equity as of June 30, 2025, and 97,578,175 shares outstanding as of February 23, 2026. The filing outlines R&D strategy, collaboration payments and milestones, intellectual property positions, manufacturing reliance on CMOs, and regulatory pathways for oncology and CNS programs.
C4 Therapeutics is asking stockholders to vote at its 2026 virtual annual meeting on four items: electing three Class III directors, an advisory vote on executive pay, ratifying KPMG as auditor, and amending the 2020 Stock Option and Incentive Plan’s evergreen provision to count pre-funded warrants.
The proxy highlights 2025 progress, including advancing lead degrader cemsidomide into Phase 2 and Phase 1b multiple myeloma studies, launching a new discovery strategy in inflammation, neuroinflammation and neurodegeneration, and deepening collaborations with Biogen, Merck KGaA and Roche. The company also raised $125 million in an underwritten offering, extending its cash runway to the end of 2028.
C4 Therapeutics Inc Schedule 13G/A amendment shows Wasatch Advisors beneficially owned 4,581,761 shares of common stock, representing 4.7% of the class as reported. The filing lists sole voting and sole dispositive power over the same 4,581,761 shares. Signature date is 04/22/2026.
C4 Therapeutics, Inc. reported that its Board of Directors approved an immediate amendment to the company’s second amended and restated by-laws on April 9, 2026. The change designates the U.S. District Courts for the District of Massachusetts and the District of Delaware as the exclusive forums for resolving federal securities law claims, unless the company agrees in writing to another forum.
The amendment covers actions arising under the Securities Act of 1933, the Securities Exchange Act of 1934, and related rules and regulations. The Board adopted this forum selection provision in response to recent amendments to Delaware corporate law. The full text of the by-laws amendment is filed as an exhibit.
C4 Therapeutics, Inc. entered into a major research collaboration and license agreement with Roche to discover, develop and commercialize degrader‑antibody conjugates (DACs) for oncology. C4T grants Roche a worldwide, exclusive license for DACs against two undisclosed cancer targets, while Roche funds all development, regulatory, manufacturing and commercialization activities.
C4T will receive a $20.0 million upfront cash payment and is eligible for over $1.0 billion in development, regulatory and commercial milestone payments, plus tiered royalties ranging from mid‑single digit to low‑double digit percent on net sales. Roche also holds an option, for an additional fee, to add a third oncology target with its own milestones and royalties. The agreement can be terminated for customary reasons, and Roche may also terminate for convenience with 90 days’ notice.
Anderson Kenneth Carl reported acquisition or exercise transactions in this Form 4 filing.
C4 Therapeutics director Kenneth Carl Anderson received a grant of 4,259 shares of common stock of C4 Therapeutics, Inc. as compensation for his services as a non-employee director, in lieu of cash fees. The grant was valued at $2.70 per share, based on the closing market price on April 1, 2026. Following this award, he holds 68,230 shares directly, and additional shares are held indirectly through several irrevocable and revocable trusts, for which he disclaims beneficial ownership except to the extent of his pecuniary interest.
GROGAN DONNA ROY reported acquisition or exercise transactions in this Form 4 filing.
C4 Therapeutics director Donna Roy Grogan received 5,370 shares of common stock as compensation. The shares were issued under the company’s Non-Employee Director Compensation Policy, where she elected stock instead of cash fees for board service.
The value was based on the closing market price of $2.70 per share on April 1, 2026. After this grant, she directly holds 71,512 shares of C4 Therapeutics common stock.
CCCC submitted a Form 144 notice for the proposed sale of 101,175 shares of common stock via a stock option exercise to be effected on 03/09/2026. The filing also records a prior sale of 11,517 shares on 02/17/2026 with proceeds shown as $21,193.82.